Odin HCG 5000IU US

Human Chorionic Gonadotropin is a potent polypeptide hormone that occurs in pregnant women. It is primarily used therapeutically for conditions such as cryptorchidism, female infertility, hypogonadism (low testosterone), and weight loss.

Many users of anabolic steroids also incorporate HCG either during or after steroid use. When taken during a steroid cycle, the purpose is to mitigate the hormonal suppression that steroids induce. Post-steroid use, HCG is utilized to support recovery and enhance the hormonal reset of the body.

One of the key contemporary uses of HCG is as a weight loss aid. The HCG diet has gained notable traction in western medical circles, yet its actual effectiveness remains a contentious subject. The American Medical Association and the American Society of Bariatric Physicians have both criticized the HCG diet, asserting that any observed weight loss is primarily due to the extreme caloric restriction inherent in such a regimen, which can limit daily intake to around 500 calories. Furthermore, research indicates that HCG does not possess thyroid-stimulating properties, is not a beta-2 agonist, does not suppress appetite, nor does it demonstrate any thermogenic or fat-burning characteristics. While numerous physicians have reported weight loss success with the HCG diet, the reliance on starvation has raised concerns about its long-term health implications. There is currently no conclusive evidence demonstrating that weight loss attributed to the HCG diet occurs independently of the caloric restriction imposed by the diet itself, and this debate is likely to persist for years.

The impact of HCG on anabolic steroid users can be categorized into two phases: use during steroid cycles and post-cycle therapy (PCT). Anabolic steroid use can significantly suppress natural testosterone production, with the extent of suppression varying based on the specific steroids employed and their dosages. Following the termination of steroid use, natural testosterone production can resume, though this process is gradual. Users may experience symptoms associated with low testosterone, including muscle loss due to increased cortisol levels. To facilitate recovery, many steroid users devise a PCT plan to accelerate this process. While PCT does not immediately normalize testosterone levels, it ensures sufficient testosterone is available for bodily functions during the recovery phase.

Numerous PCT strategies exist, most commonly incorporating SERMs like Nolvadex (Tamoxifen Citrate) and/or Clomid (Clomiphene Citrate). Some individuals have discovered that initiating PCT with HCG before introducing SERMs may enhance recovery outcomes, as HCG mimics luteinizing hormone (LH) and prepares the body for subsequent SERM administration, facilitating a more effective recovery.

The additional benefit of HCG for steroid users involves its use during steroid cycles. Given that anabolic steroids can lead to testicular atrophy from suppressed natural testosterone levels, supplementing with HCG can help maintain testicular size. This effect, while largely cosmetic, might offer benefits by keeping the body supplied with exogenous LH, which can ease recovery after steroid cessation. However, caution is advised as the body can develop a dependency on HCG for LH, unlike with anabolic steroids. For individuals not suffering from low testosterone, it is crucial to carefully regulate HCG use during cycles to prevent the onset of LH dependency. Many steroid users have inadvertently caused more harm through excessive HCG use compared to anabolic steroids. Thus, responsible HCG administration is essential, whether utilized during steroid cycles or as a precursor to PCT.

For anabolic steroid users employing HCG during cycles, a common dosage is 250 IU every 4-5 days, which is sufficient to achieve desired results without risking the suppression of natural testosterone production.

During PCT, two effective HCG protocols exist. The first involves administering 1,500 to 4,000 IU every 3-4 days for 2-3 weeks, followed by the introduction of SERM therapy. An alternative, potentially more effective method, is daily HCG administration at doses of 500 to 1,000 IU for ten consecutive days, after which SERM therapy begins.

Timing is critical when using HCG during PCT. If the steroid cycle concludes with long-acting esters, HCG therapy should start 10 days after the last injection, progressing to SERM therapy post-HCG. Conversely, if the last cycle employs short-acting esters, HCG therapy should commence three days following the last injection, followed by SERM therapy afterward.